Other

Oregon Health & Science University

University of Kansas

Debiopharm S.a.

Congenia S.r.l.

Paolo Bernardi

William Brusilow

Michael Forte

Stephen Martin Courtney

Frank John Schoenen

Christopher John Yarnold

Saverio Minucci

Aaron Nilsen

Grégoire Vuagniaux

Michael Cohen

Gilles Pain

Jordan Devereaux

Rafael Crabbé

Justina Sileikyte

Sudeshna Roy

PierGiuseppe Pellicci

Marco Giorgio

Joachim Kraemer

The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof wherein Ris selected from the group of H, halogen, and C-Calkyl; and Ris selected from the group of H, CF, and halogen; with the proviso that at least one of Rand Ris halogen or CF.

Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability

Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.

Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response

The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)

Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response

Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.

The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.

Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy

The invention discloses the use of a compound of formula (I), wherein R, R, R, and Reach independently represents: hydrogen; halo; hydroxy; (C-C) alkyl optionally substituted by hydroxy or (C-C) alkoxy; (C-C) haloalkyl; (C-C) alkoxy; and (C-C) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds. 

Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT

Growing community of inventors

Padua, Italy

Paolo Bernardi